This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
SRPT Beats on Q3 Earnings & Sales, Discontinues PPMO-Based DMD Program
by Zacks Equity Research
Sarepta posts encouraging Q3 earnings. After conducting a risk-benefit analysis, the company decides to stop developing the entire PPMO program.
Sarepta Therapeutics (SRPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Sarepta Therapeutics (SRPT) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Viatris to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
VTRS' Q3 results are likely to gain from new product launches in all major geographies.
Gilead Science to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors' focus is likely to be on GILD???s HIV franchise performance and oncology sales when the company reports third-quarter 2024 results.
Implied Volatility Surging for Sarepta Therapeutics (SRPT) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Sarepta Therapeutics (SRPT) stock based on the movements in the options market lately.
Why Is Sarepta Therapeutics (SRPT) Down 1.9% Since Last Earnings Report?
by Zacks Equity Research
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Dyne Reports Mixed Data From DMD Study, Key Executives Step Down
by Zacks Equity Research
DYN's shares plummet following mixed data from its ongoing DMD study. Senior executives of the company step down.
Down -10.33% in 4 Weeks, Here's Why You Should You Buy the Dip in Sarepta Therapeutics (SRPT)
by Zacks Equity Research
Sarepta Therapeutics (SRPT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Sarepta (SRPT) Q2 Earnings Top Estimates, Sales Lag, View Weak
by Zacks Equity Research
Sarepta (SRPT) reports mixed results in the second quarter. It issues revenue guidance for 2025, which is below expectations. Stock falls during after-market trading.
Compared to Estimates, Sarepta Therapeutics (SRPT) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Sarepta Therapeutics (SRPT) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
What Makes Sarepta Therapeutics (SRPT) a New Buy Stock
by Zacks Equity Research
Sarepta Therapeutics (SRPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks Industry Outlook Highlights Moderna, Sarepta Therapeutics, Halozyme Therapeutics, Krystal Biotech and Axsome Therapeutics
by Zacks Equity Research
Moderna, Sarepta Therapeutics, Halozyme Therapeutics, Krystal Biotech and Axsome Therapeutics have been highlighted in this Industry Outlook article.
5 Biotech Stocks to Bet On Bright Industry Prospects
by Ekta Bagri
New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position MRNA, SRPT, HALO, KRYS and AXSM well in this volatile sector.
Wall Street Analysts Believe Sarepta Therapeutics (SRPT) Could Rally 38.04%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 38% in Sarepta Therapeutics (SRPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
What Makes Sarepta Therapeutics (SRPT) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Sarepta Therapeutics (SRPT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here's Why Sarepta (SRPT) Stock Price Surged 57% YTD
by Zacks Equity Research
Sarepta (SRPT) surges on the commercial potential of its Elevidys, the first FDA-approved gene therapy for Duchenne muscular dystrophy.
Best Momentum Stocks to Buy for July 3rd
by Zacks Equity Research
SRPT and ASYS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 3, 2024.
New Strong Buy Stocks for July 3rd
by Zacks Equity Research
MONDY, MWA, SRPT, ASYS and CLCO have been added to the Zacks Rank #1 (Strong Buy) List on July 3, 2024.
Biotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates
by Zacks Equity Research
Alnylam Pharmaceuticals (ALNY) and Alimera Sciences, Inc. (ALIM) are in the spotlight following study and merger updates, respectively.
Roche's (RHHBY) Ocrevus Subcutaneous Gets European Commission Nod
by Zacks Equity Research
Roche (RHHBY) obtains approval for the subcutaneous formulation of relapsing multiple sclerosis drug Ocrevus in Europe. In addition, a review of the company's MAA for gene therapy, Elevidys, is also underway.
Company News for Jun 24, 2024
by Zacks Equity Research
Companies In The News Are: FDS, SRPT, HTZ, ASAN.
Sarepta Therapeutics (SRPT) Soars 30.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Sarepta Therapeutics (SRPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
FDA Expands Sarepta's (SRPT) DMD Gene Therapy Label
by Zacks Equity Research
Following the label expansion, Sarepta's (SRPT) Elevidys is approved to treat all DMD patients aged four years and older, regardless of ambulation status.
Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal
by Zacks Equity Research
Pfizer's (PFE) phase III study, CIFFREO, fails to show improvement in motor function in ambulatory boys with DMD treated with its gene therapy fordadistrogene movaparvovec compared to placebo.
Sarepta Therapeutics (SRPT) Down 4.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.